FeesSafety
Pluang+

XORTX completes clinical drug supply manufacturing for gout treatment trial XRX-OXY-102

Company Fundamentals
16 Nov 2026, 15:05 WIB
GlobeNewsWire
View Source
Bullish
XORTX completes clinical drug supply manufacturing for gout treatment trial XRX-OXY-102

XORTX Therapeutics has finished manufacturing and packaging the clinical drug supply for its XRX-OXY-102 trial, targeting gout treatment with its proprietary XORLO™ oxypurinol formulation. This milestone supports their Clinical Trial Application to Health Canada and planned Investigational New Drug filing with the FDA. The trial will assess the drug's pharmacokinetics and therapeutic equivalence to allopurinol, aiming for marketing approval. Successful development could offer a safer alternative for gout patients intolerant to current treatments.

XORTX Therapeutics' clinical drug supply completion provides context for health sector trading. For readers following health stocks, here is Pluang's market snapshot as of Nov 16, 2026 19:13 WIB: Out of 150 priced US health stocks, 67 rose and 61 fell. Notable movers include HNGE at USD 112.25 with a -2.72% change and a typical hold time of 12 days, ABCL at USD 11.21 down 2.44% with a 42-day hold, and RXRX at USD 3.11 down 2.35% with a 23-day hold.

More News

Nike faces scrutiny over cost-cutting ahead of first investor day since 2017

Nike faces scrutiny over cost-cutting ahead of first investor day since 2017

Nike is under pressure to clarify its cost-cutting plans as it prepares for its first investor day since 2017, scheduled for November 16–17. Despite efforts led by CEO Elliott Hill to turn the company around, management expects revenue to decline by ...

Market News
Bearish
55 minutes ago
Jackery and Every Electric launch North America's first plug-in virtual power plant for renters in NYC.

Jackery and Every Electric launch North America's first plug-in virtual power plant for renters in NYC.

Jackery and Every Electric have partnered to create North America's first plug-and-play virtual power plant (VPP) for renters and apartment residents, starting in New York City. This innovative system uses portable power stations plugged into standar...

Market News
Bullish
1 hour ago
P-1 AI names retired Brig. Gen. Matt Isler GM for Aerospace and Defense to boost AI engineering efforts.

P-1 AI names retired Brig. Gen. Matt Isler GM for Aerospace and Defense to boost AI engineering efforts.

P-1 AI has appointed retired Brigadier General Matt Isler as General Manager for its Aerospace and Defense division. Isler brings nearly 30 years of military and industry experience, including leadership roles at Northrop Grumman and startup DEFCON A...

Market News
Bullish
1 hour ago
Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo Inc. has renewed its Normal Course Issuer Bid (NCIB), allowing it to repurchase up to 22.5 million common shares, representing 10% of its public float, from November 19, 2026, to November 18, 2027. This move reflects Saputo's strategy to retur...

Company Fundamentals
Bullish
2 hours ago
GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian has launched the Enterprise Good Samaritan Program to identify and notify companies about high-impact leaked credentials that could expose their systems to attackers. Using AI and expert analysis, the program traces leaks to affected orga...

Market News
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App